Who is sponsoring NCT03739983?

NCT03739983 is sponsored by University of Wisconsin, Madison.

What condition does NCT03739983 study?

NCT03739983 studies Adherence, Medication.

What drugs are being tested in NCT03739983?

Interventions: Vaginal Renewal Program.

What is the status of NCT03739983?

NCT03739983 is currently TERMINATED.

Last reviewed 2021-10-20 · How we verify

Alterations in the Vaginal Microenvironment Using a Non-pharmacological Intervention

NCT03739983 PHASE2 TERMINATED Results posted

Breast cancer patients commonly take medications to reduce the risk of recurrence, including aromatase inhibitors (AIs). AIs can cause significant side effects that reduce patient adherence. Early discontinuation of AI therapy results in an increased risk of cancer recurrence and increased risk of breast cancer-related death. Common side effects include vaginal dryness and vulvovaginal atrophy leading to worsening sexual function. To increase AI adherence, the investigators will study a non-pharmaceutical Vaginal Renewal Program (VRP) aimed at stimulating nitric oxide production to consequently increase vaginal lubrication, and improve the symptoms of vulvovaginal atrophy.

Details

Lead sponsor	University of Wisconsin, Madison
Phase	PHASE2
Status	TERMINATED
Enrolment	2
Start date	Tue Nov 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Mar 10 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Adherence, Medication

Interventions

Vaginal Renewal Program

Countries

United States